Chembio Diagnostics - Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2020 adjusted for splits. The latest closing stock price for Chembio Diagnostics as of October 19, 2020 is 4.95.
  • The all-time high Chembio Diagnostics stock closing price was 16.00 on June 09, 2004.
  • The Chembio Diagnostics 52-week high stock price is 15.89, which is 221% above the current share price.
  • The Chembio Diagnostics 52-week low stock price is 2.25, which is 54.5% below the current share price.
  • The average Chembio Diagnostics stock price for the last 52 weeks is 5.76.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 6.0100 5.6600 7.8500 3.9400 4.5600 -19.43%
2018 8.7806 8.1000 11.5000 4.9500 5.6600 -30.98%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
2004 10.2441 9.2000 16.0000 4.8000 5.7600 0.00%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.098B $0.034B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $194.174B 36.44
Medtronic (MDT) Ireland $148.038B 27.88
Stryker (SYK) United States $83.980B 32.56
Boston Scientific (BSX) United States $54.995B 31.77
Lonza Group Ag (LZAGY) Switzerland $48.550B 0.00
Baxter (BAX) United States $41.420B 0.00
Zimmer Biomet Holdings (ZBH) United States $30.422B 25.25
EssilorLuxottica Societe Anonyme (ESLOY) France $29.732B 0.00
Terumo (TRUMY) Japan $29.086B 37.18
ResMed (RMD) United States $26.198B 37.98
Sunny Optical Technology (SNPTF) China $17.297B 0.00
Smith & Nephew SNATS (SNN) United Kingdom $17.198B 0.00
Bio-Rad Laboratories (BIO) United States $16.518B 74.71
Insulet (PODD) United States $16.303B 689.81
DiaSorin S.p.A (DSRLF) Italy $12.169B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $11.080B 0.00
Quidel (QDEL) United States $10.708B 56.72
GN STORE NORD (GNNDY) Denmark $9.996B 50.95
William Demant Holdings (WILYY) Denmark $7.850B 0.00
Canopy Growth (CGC) Canada $6.603B 0.00
Perrigo (PRGO) Ireland $6.466B 11.10
Hill-Rom Holdings (HRC) United States $5.963B 14.80
Haemonetics (HAE) United States $4.755B 31.68
Envista Holdings (NVST) United States $4.286B 29.23
Hutchison China MediTech (HCM) Hong Kong, SAR China $4.232B 0.00
ICU Medical (ICUI) United States $4.170B 31.82
TG Therapeutics (TGTX) United States $3.824B 0.00
Neogen (NEOG) United States $3.788B 62.10
Abcam (ABCZY) $3.534B 0.00
National Vision Holdings (EYE) United States $3.282B 510.13
GW Pharmaceuticals (GWPH) United Kingdom $2.964B 0.00
NuVasive (NUVA) United States $2.742B 38.21
Agios Pharmaceuticals (AGIO) United States $2.479B 0.00
DFB Healthcare Acquisitions (AHCO) United States $2.373B 0.00
AtriCure (ATRC) United States $1.828B 0.00
Owens & Minor (OMI) United States $1.649B 36.94
Cardiovascular Systems (CSII) United States $1.548B 0.00
NanoString Technologies (NSTG) United States $1.527B 0.00
Aphria (APHA) Canada $1.343B 0.00
MacroGenics (MGNX) United States $1.321B 0.00
InMode (INMD) Israel $1.269B 32.02
Quanterix (QTRX) United States $1.204B 0.00
Cerus (CERS) United States $1.068B 0.00
OraSure Technologies (OSUR) United States $0.988B 0.00
PetIQ (PETQ) United States $0.932B 26.73
BioLife Solutions (BLFS) United States $0.901B 469.50
Lantheus Holdings (LNTH) United States $0.892B 12.36
Meridian Bioscience (VIVO) United States $0.775B 17.90
Vapotherm (VAPO) United States $0.759B 0.00
Phibro Animal Health (PAHC) United States $0.737B 16.87
LeMaitre Vascular (LMAT) United States $0.654B 39.89
Eagle Pharmaceuticals (EGRX) United States $0.632B 89.33
Omeros (OMER) United States $0.628B 0.00
Surmodics (SRDX) United States $0.567B 62.19
Varex Imaging (VREX) United States $0.533B 23.08
Zynex (ZYXI) United States $0.488B 42.61
Aurora Cannabis (ACB) Canada $0.464B 0.00
Surface Oncology (SURF) United States $0.376B 0.00
Cytosorbents (CTSO) United States $0.369B 0.00
HEXO (HEXO) $0.361B 0.00
Viemed Healthcare (VMD) United States $0.345B 12.32
Utah Medical Products (UTMD) United States $0.301B 25.82
InfuSystems Holdings (INFU) United States $0.264B 50.31
SEMPERIT AG HLD (SEIGY) Austria $0.257B 0.00
Neptune Wellness Solutions (NEPT) Canada $0.249B 0.00
Organigram Holdings (OGI) Canada $0.230B 0.00
Bovie Medical (APYX) United States $0.203B 0.00
Exagen (XGN) United States $0.201B 0.00
Wound Management Technologies (SMTI) United States $0.193B 0.00
Female Health (VERU) United States $0.179B 0.00
Chimerix (CMRX) United States $0.178B 0.00
Evolus (EOLS) United States $0.141B 0.00
Fonar (FONR) United States $0.137B 18.16
Liberty Health Sciences (LHSIF) United States $0.128B 0.00
Capricor Therapeutics (CAPR) United States $0.094B 0.00
Green Organic Dutchman Holdings (TGODF) Canada $0.081B 0.00
Rockwell Medical (RMTI) United States $0.077B 0.00
United-Guardian (UG) United States $0.069B 15.57
Trinity Biotech (TRIB) Ireland $0.066B 12.55
MTech Acquisition (KERN) United States $0.065B 0.00
Brainsway (BWAY) Israel $0.065B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.063B 0.00
Nephros (NEPH) United States $0.059B 0.00
ImmuCell (ICCC) United States $0.041B 0.00
FSD PHARMA INC (HUGE) Canada $0.028B 0.00
Conatus Pharmaceuticals (HSTO) United States $0.028B 0.00
NF Energy Saving (BIMI) China $0.020B 0.00
Akers Biosciences Inc (AKER) United States $0.020B 0.00
GUARDION HEALTH (GHSI) United States $0.018B 0.00
Myomo (MYO) United States $0.016B 0.00
NeuroMetrix (NURO) United States $0.006B 0.00
Senestech (SNES) United States $0.006B 0.00